A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel
Status:
Terminated
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
This is a single-center, open-label (sequential-group dose-escalation dose-finding) phase I
study of satraplatin and docetaxel in patients who have received prior chemotherapy regimens.
Once the MTD is determined, an additional 6 patients, all with chemotherapy-naïve HRPC, will
be enrolled. Once a recommended dose(s) (RD(s)) for phase 2 studies has/have been determined,
6 additional patients with chemotherapy-naïve HRPC will be enrolled at the RD to further
evaluate safety and efficacy.